Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Stock Information for Cazoo Group Ltd Class A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cazoo Group Ltd Class A

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology Announces Proposed Public Offering of Common Stock
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.